In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug-resistant aerobic gram-negative bacilli

Antimicrobial Agents and Chemotherapy

Volumn 64, Issue 2, 2020, Pages

  Fleischmann, Wim A ^a,b   Greenwood Quaintance, Kerryl E ^b   Patel, Robin ^b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b MAYO CLINIC   (United States)

Author keywords

Antimicrobial resistance; Enterobacterales; Plazomicin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE; BETA LACTAMASE CTX M; BETA LACTAMASE NDM; BETA LACTAMASE OXA 48 LIKE; GENTAMICIN; PLAZOMICIN; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; SISOMICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CITROBACTER; CITROBACTER FREUNDII; CITROBACTER KOSERI; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE AEROBIC RODS AND COCCI; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROVIDENCIA STUARTII; SERRATIA MARCESCENS; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENTAMICINS; GRAM-NEGATIVE AEROBIC BACTERIA; MICROBIAL SENSITIVITY TESTS; SISOMICIN; TOBRAMYCIN;

EID: 85078563792     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01711-19     Document Type: Article

References (36)

1. U. S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. https://www. cdc. gov/drugresistance/threat-report-2013/ pdf/ar-threats-2013-508. pdf. Accessed 21 April 2019.
2. World Health Organization. 2017. Global priority list of antibioticresistant bacteria to guide research, discovery, and development of new antibiotics. https://www. who. int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed 21 April 2019.
3. Kotra LP, Haddad J, Mobashery S. 2000. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 44: 3249-3256. https://doi. org/10. 1128/aac. 44. 12. 3249-3256. 2000.
4. Cross AS, Opal S, Kopecko DJ. 1983. Progressive increase in antibiotic resistance of Gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance. Arch Intern Med 143: 2075-2080. https://doi. org/10. 1001/ archinte. 1983. 00350110053015.
5. Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. Drug Resist Updat 13: 151-171. https://doi. org/10. 1016/j. drup. 2010. 08. 003.
6. Ballaben AS, Andrade LN, Galetti R, Ferreira JC, McElheny CL, Mettus RT, da Silva P, de Oliveira Garcia D, Darini ALC, Doi Y. 2018. Diversity of high-level aminoglycoside resistance mechanisms among Gramnegative nosocomial pathogens in Brazil. Antimicrob Agents Chemother 62: e01550-18. https://doi. org/10. 1128/AAC. 01550-18.
7. Garneau-Tsodikova S, Labby KJ. 2016. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. Medchemcomm 7: 11-27. https://doi. org/10. 1039/C5MD00344J.
8. Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2012. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 10: 459-473. https://doi. org/10. 1586/eri. 12. 25.
9. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54: 4636-4642. https://doi. org/10. 1128/AAC. 00572-10.
10. Franklin K, Clarke AJ. 2001. Overexpression and characterization of the chromosomal aminoglycoside 2=-N-acetyltransferase of Providencia stuartii. Antimicrob Agents Chemother 45: 2238-2244. https://doi. org/10. 1128/AAC. 45. 8. 2238-2244. 2001.
11. Cox G, Ejim L, Stogios PJ, Koteva K, Bordeleau E, Evdokimova E, Sieron AO, Savchenko A, Serio AW, Krause KM, Wright GD. 2018. Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis 4: 980-987. https://doi. org/10. 1021/acsinfecdis. 8b00001.
12. Schmidt-Malan SM, Mishra AJ, Mushtaq A, Brinkman CL, Patel R. 2018. In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant Gram-negative bacilli. Antimicrob Agents Chemother 62: e00533-18. https://doi. org/10. 1128/AAC. 00533-18.
13. Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. 2018. In vitro activity of plazomicin against Gram-negative and Grampositive isolates collected from U. S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob Agents Chemother 62: e00313-18. https://doi. org/10. 1128/AAC. 00313-18.
14. Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M, Study Collaborators. 2019. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect Dis 19: 167. https://doi. org/10. 1186/s12879-019-3801-1.
15. Lopez-Diaz MD, Culebras E, Rodriguez-Avial I, Rios E, Vinuela-Prieto JM, Picazo JJ, Rodriguez-Avial C. 2017. Plazomicin activity against 346 extended-spectrum-beta-lactamase/AmpC-producing Escherichia coli urinary isolates in relation to aminoglycoside-modifying enzymes. Antimicrob Agents Chemother 61: e02454-16. https://doi. org/10. 1128/AAC. 02454-16.
16. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66: 48-53. https://doi. org/10. 1093/jac/dkq408.
17. Martins AF, Bail L, Ito CAS, da Silva Nogueira K, Dalmolin TV, Martins AS, Rocha JLL, Serio AW, Tuon FF. 2018. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers. Diagn Microbiol Infect Dis 90: 228-232. https://doi. org/ 10. 1016/j. diagmicrobio. 2017. 11. 004.
18. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-beta-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53: 5046-5054. https://doi. org/10. 1128/AAC. 00774-09.
19. Hidalgo L, Hopkins KL, Gutierrez B, Ovejero CM, Shukla S, Douthwaite S, Prasad KN, Woodford N, Gonzalez-Zorn B. 2013. Association of the novel aminoglycoside resistance determinant RmtF with NDM carbapenemase in Enterobacteriaceae isolated in India and the UK. J Antimicrob Chemother 68: 1543-1550. https://doi. org/10. 1093/jac/dkt078.
20. Taylor E, Sriskandan S, Woodford N, Hopkins KL. 2018. High prevalence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacteriaceae in the UK and Ireland. Int J Antimicrob Agents 52: 278-282. https://doi. org/10. 1016/j. ijantimicag. 2018. 03. 016.
21. Serio AW, Keepers T, Krause KM. 2019. Plazomicin is active against metallo-beta-lactamase-producing Enterobacteriaceae. Open Forum Infect Dis 6: ofz123. https://doi. org/10. 1093/ofid/ofz123.
22. Kohner PC, Robberts FJ, Cockerill FR, III, Patel R. 2009. Cephalosporin MIC distribution of extended-spectrum-beta-lactamase-and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol 47: 2419-2425. https://doi. org/10. 1128/JCM. 00508-09.
23. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De PP, Koh TH, Patel R. 2015. In vitro activities of ceftazidimeavibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gramnegative bacilli. Antimicrob Agents Chemother 59: 7842-7846. https:// doi. org/10. 1128/AAC. 02019-15.
24. Balm MN, La MV, Krishnan P, Jureen R, Lin RT, Teo JW. 2013. Emergence of Klebsiella pneumoniae co-producing NDM-type and OXA-181 carbapenemases. Clin Microbiol Infect 19: E421-E423. https://doi. org/10. 1111/ 1469-0691. 12247.
25. Cunningham SA, Noorie T, Meunier D, Woodford N, Patel R. 2013. Rapid and simultaneous detection of genes encoding Klebsiella pneumoniae carbapenemase (blaKPC) and New Delhi metallo-beta-lactamase (blaNDM) in Gram-negative bacilli. J Clin Microbiol 51: 1269-1271. https://doi. org/ 10. 1128/JCM. 03062-12.
26. Koh TH, Cao D, Shan QY, Bacon A, Hsu LY, Ooi EE. 2013. Acquired carbapenemases in Enterobacteriaceae in Singapore, 1996-2012. Pathology 45: 600-603. https://doi. org/10. 1097/PAT. 0b013e3283650b1e.
27. Poirel L, Heritier C, Tolun V, Nordmann P. 2004. Emergence of oxacillinasemediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48: 15-22. https://doi. org/10. 1128/aac. 48. 1. 15-22. 2004.
28. Teo J, Ngan G, Balm M, Jureen R, Krishnan P, Lin R. 2012. Molecular characterization of NDM-1 producing Enterobacteriaceae isolates in Singapore hospitals. Western Pac Surveill Response J 3: 19-24. https://doi. org/10. 5365/WPSAR. 2011. 2. 4. 010.
29. Teo JW, Kurup A, Lin RT, Hsien KT. 2013. Emergence of clinical Klebsiella pneumoniae producing OXA-232 carbapenemase in Singapore. New Microbes New Infect 1: 13-15. https://doi. org/10. 1002/ 2052-2975. 4.
30. Teo JW, La MV, Krishnan P, Ang B, Jureen R, Lin RT. 2013. Enterobacter cloacae producing an uncommon class A carbapenemase, IMI-1, from Singapore. J Med Microbiol 62: 1086-1088. https://doi. org/10. 1099/jmm. 0. 053363-0.
31. Robberts FJ, Kohner PC, Patel R. 2009. Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates. J Clin Microbiol 47: 358-361. https://doi. org/10. 1128/JCM. 01687-08.
32. Cunningham SA, Vasoo S, Patel R. 2016. Evaluation of the Check-Points Check MDR CT103 and CT103 XL microarray kits by use of preparatory rapid cell lysis. J Clin Microbiol 54: 1368-1371. https://doi. org/10. 1128/ JCM. 03302-15.
33. Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing, 29th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.
34. Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. CLSI document M07. Clinical and Laboratory Standards Institute, Wayne, PA.
35. European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters, version 9. 0. http: //www. eucast. org. Accessed 15 May 2019.
36. U. S. Food and Drug Administration. Plazomicin-injection. FDAidentified interpretive criteria. https://www. fda. gov/drugs/development-resources/plazomicin-injection. Accessed 19 May 2019.